(1) Bauer, R. A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today 2015, 20, 1061−1073.
(2) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011, 10, 307−317.
(3) Long, M. J. C.; Aye, Y. Privileged Electrophile Sensors: A Resource for Covalent Drug Development. Cell Chem. Biol. 2017, 24, 787−800.
(4) Zhang, T.; Hatcher, J. M.; Teng, M.; Gray, N. S.; Kostic, M. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chem. Biol. 2019, 26, 1486−1500.
(5) Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 2012, 55, 6243−6262.
(6) Baillie, T. A. Targeted Covalent Inhibitors for Drug Design. Angew. Chem. Int. Ed. Engl. 2016, 55, 13408−13421.
(7) Cohen, M. S.; Zhang, C.; Shokat, K. M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005, 308, 1318−1321.
(8) Bradshaw, J. M.; McFarland, J. M.; Paavilainen, V. O.; Bisconte, A.; Tam, D.; Phan, V. T.; Romanov, S.; Finkle, D.; Shu, J.; Patel, V.; et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol. 2015, 11, 525−531.
(9) McAulay, K.; Hoyt, E. A.; Thomas, M.; Schimpl, M.; Bodnarchuk, M. S.; Lewis, H. J.; Barratt, D.; Bhavsar, D.; Robinson, D. M.; Deery, M. J.; et al. Alkynyl Benzoxazines and Dihydroquinazo- lines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. J. Am. Chem. Soc. 2020, 142, 10358−10372.
(10) Matthews, D. A.; Dragovich, P. S.; Webber, S. E.; Fuhrman, S. A.; Patick, A. K.; Zalman, L. S.; Hendrickson, T. F.; Love, R. A.; Prins, T. J.; Marakovits, J. T.; et al. Structure-assisted design of mechanism- based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 11000−11007.
(11) Schnute, M. E.; Benoit, S. E.; Buchler, I. P.; Caspers, N.; Grapperhaus, M. L.; Han, S.; Hotchandani, R.; Huang, N.; Hughes, R. O.; Juba, B. M.; et al. Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. ACS Med. Chem. Lett. 2019, 10, 80−85.
(12) Zhou, W.; Hur, W.; McDermott, U.; Dutt, A.; Xian, W.; Ficarro, S. B.; Zhang, J.; Sharma, S. V.; Brugge, J.; Meyerson, M.; et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 2010, 17, 285−295.
(13) Pettinger, J.; Jones, K.; Cheeseman, M. D. Lysine-Targeting Covalent Inhibitors. Angew. Chem. Int. Ed. Engl. 2017, 56, 15200− 15209.
(14) Mukherjee, H.; Grimster, N. P. Beyond cysteine: recent developments in the area of targeted covalent inhibition. Curr. Opin. Chem. Biol. 2018, 44, 30−38.
(15) London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermancǐc,̌P.; Bonnet, R.; Shoichet, B. K.; Taunton, J. Covalent docking of large libraries for the discovery of chemical probes. Nat. Chem. Biol. 2014, 10, 1066−1072.
(16) Resnick, E.; Bradley, A.; Gan, J.; Douangamath, A.; Krojer, T.; Sethi, R.; Geurink, P. P.; Aimon, A.; Amitai, G.; Bellini, D.; Bennett, J.; Fairhead, M.; Fedorov, O.; Gabizon, R.; Gan, J.; et al. Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. J. Am. Chem. Soc. 2019, 141, 8951−8968.
(17) Boike, L.; Cioffi, A. G.; Majewski, F. C.; Co, J.; Henning, N. J.; Jones, M. D.; Liu, G.; McKenna, J. M.; Tallarico, J. A.; Schirle, M.; Nomura, D. K. Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC. Cell Chem. Biol. 2021, 28, 4.
(18) Dubiella, C.; Pinch, B. J.; Koikawa, K.; Zaidman, D.; Poon, E.; Manz, T. D.; Nabet, B.; He, S.; Resnick, E.; Rogel, A.; et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat. Chem. Biol. 2021, 17, 954−963.
(19) Craven, G. B.; Affron, D. P.; Allen, C. E.; Matthies, S.; Greener, J. G.; Morgan, R. M. L.; Tate, E. W.; Armstrong, A.; Mann, D. J. High- Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery. Angew. Chem. Int. Ed. Engl. 2018, 57, 5257−5261.
(20) Bachovchin, D. A.; Koblan, L. W.; Wu, W.; Liu, Y.; Li, Y.; Zhao, P.; Woznica, I.; Shu, Y.; Lai, J. H.; Poplawski, S. E.; et al. A high- throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat. Chem. Biol. 2014, 10, 656−663.
(21) Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503, 548−551.
(22) Banerjee, R.; Pace, N. J.; Brown, D. R.; Weerapana, E. 1,3,5- Triazine as a modular scaffold for covalent inhibitors with streamlined target identification. J. Am. Chem. Soc. 2013, 135, 2497−2500.
(23) Abbasov, M. E.; Kavanagh, M. E.; Ichu, T. A.; Lazear, M. R.; Tao, Y.; Crowley, V. M.; Am Ende, C. W.; Hacker, S. M.; Ho, J.; Dix, M. M.; Suciu, R.; Hayward, M. M.; Kiessling, L. L.; Cravatt, B. F. A proteome-wide atlas of lysine-reactive chemistry. Nat. Chem. 2021, 1081.
(24) Kuljanin, M.; Mitchell, D. C.; Schweppe, D. K.; Gikandi, A. S.; Nusinow, D. P.; Bulloch, N. J.; Vinogradova, E. V.; Wilson, D. L.; Kool, E. T.; Mancias, J. D.; et al. Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries. Nat. Biotechnol. 2021, 39, 630−641.
(25) Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, B. D.; González-Páez, G. E.; Chatterjee, S.; Lanning, B. R.; Teijaro, J. R.; Olson, A. J.; Wolan, D. W.; Cravatt, B. F. Proteome-wide covalent ligand discovery in native biological systems. Nature 2016, 534, 570− 574.
(26) Bar-Peled, L.; Kemper, E. K.; Suciu, R. M.; Vinogradova, E. V.; Backus, K. M.; Horning, B. D.; Paul, T. A.; Ichu, T. A.; Svensson, R. U.; Olucha, J.; et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell 2017, 171, 696.
(27) Roberts, A. M.; Miyamoto, D. K.; Huffman, T. R.; Bateman, L. A.; Ives, A. N.; Akopian, D.; Heslin, M. J.; Contreras, C. M.; Rape, M.; Skibola, C. F.; et al. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem. Biol. 2017, 12, 899−904.
(28) Chung, C. Y.-S.; Shin, H. R.; Berdan, C. A.; Ford, B.; Ward, C. C.; Olzmann, J. A.; Zoncu, R.; Nomura, D. K. Covalent targeting of the vacuolar H(+)-ATPase activates autophagy via mTORC1 inhibition. Nat. Chem. Biol. 2019, 15, 776−785.
(29) Grossman, E. A.; Ward, C. C.; Spradlin, J. N.; Bateman, L. A.; Huffman, T. R.; Miyamoto, D. K.; Kleinman, J. I.; Nomura, D. K. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products. Cell Chem. Biol. 2017, 24, 1368.
(30) Vinogradova, E. V.; Zhang, X.; Remillard, D.; Lazar, D. C.; Suciu, R. M.; Wang, Y.; Bianco, G.; Yamashita, Y.; Crowley, V. M.; Schafroth, M. A.; Yokoyama, M.; Konrad, D. B.; Lum, K. M.; Simon, G. M.; Kemper, E. K.; Lazear, M. R.; Yin, S.; Blewett, M. M.; Dix, M. M.; Nguyen, N.; Shokhirev, M. N.; Chin, E. N.; Lairson, L. L.; Melillo, B.; Schreiber, S. L.; Forli, S.; Teijaro, J. R.; Cravatt, B. F. An Activity- Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell 2020, 182, 1009.
(31) Crowley, V. M.; Thielert, M.; Cravatt, B. F. Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization. ACS Cent. Sci. 2021, 7, 613−623.
(32) Brighty, G. J.; Botham, R. C.; Li, S.; Nelson, L.; Mortenson, D. E.; Li, G.; Morisseau, C.; Wang, H.; Hammock, B. D.; Sharpless, K. B.; et al. Using sulfuramidimidoyl fluorides that undergo sulfur(VI) fluoride exchange for inverse drug discovery. Nat. Chem. 2020, 12, 906−913.
(33) Ábrányi-Balogh, P.; Petri, L.; Imre, T.; Szijj, P.; Scarpino, A.; Hrast, M.; Mitrovic,́A.; Fonovic,́U. P.; Németh, K.; Barreteau, H.; Roper, D. I.; Korvati, K.; Ferenczy, G. G.; Kos, J.; Ilas, J.; Gobec, S.; Keseru, G. M. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur. J. Med. Chem. 2018, 160, 94−107.
(34) Takaya, J.; Mio, K.; Shiraishi, T.; Kurokawa, T.; Otsuka, S.; Mori, Y.; Uesugi, M. A Potent and Site-Selective Agonist of TRPA1. J. Am. Chem. Soc. 2015, 137, 15859−15864.
(35) Chen, Y. C.; Backus, K. M.; Merkulova, M.; Yang, C.; Brown, D.; Cravatt, B. F.; Zhang, C. Covalent Modulators of the Vacuolar ATPase. J. Am. Chem. Soc. 2017, 139, 639−642.
(36) Yu, Y.; Hamza, A.; Zhang, T.; Gu, M.; Zou, P.; Newman, B.; Li, Y.; Gunatilaka, A. A. L.; Zhan, C. G.; Sun, D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem. Pharmacol. 2010, 79, 542−551.
(37) Chen, Y.; Zhu, J. Y.; Hong, K. H.; Mikles, D. C.; Georg, G. I.; Goldstein, A. S.; Amory, J. K.; Schönbrunn, E. Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem. Biol. 2018, 13, 582−590.
(38) Low, W. K.; Dang, Y.; Schneider-Poetsch, T.; Shi, Z.; Choi, N. S.; Merrick, W. C.; Romo, D.; Liu, J. O. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell 2005, 20, 709−722.
(39) Cole, K. S.; Grandjean, J. M. D.; Chen, K.; Witt, C. H.; O’Day, J.; Shoulders, M. D.; Wiseman, R. L.; Weerapana, E. Characterization of an A-Site Selective Protein Disulfide Isomerase A1 Inhibitor. Biochemistry 2018, 57, 2035−2043.
(40) Yun, J.; Mullarky, E.; Lu, C.; Bosch, K. N.; Kavalier, A.; Rivera, K.; Roper, J.; Chio, I. I.; Giannopoulou, E. G.; Rago, C.; et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015, 350, 1391−1396.
(41) Kunjithapatham, R.; Ganapathy-Kanniappan, S. GAPDH with NAD(+)-binding site mutation competitively inhibits the wild-type and affects glucose metabolism in cancer. Biochim. Biophys. Acta Gen. Subj. 2018, 1862, 2555−2563.
(42) Boroughs, L. K.; DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015, 17, 351−359.
(43) Wagener, J.; Schneider, J. J.; Baxmann, S.; Kalbacher, H.; Borelli, C.; Nuding, S.; Küchler, R.; Wehkamp, J.; Kaeser, M. D.; Mailänder-Sanchez, D.; Braundorf, C.; Hube, B.; Schild, L.; Forssmann, W.-G.; Korting, H.-C.; Liepke, C.; Schaller, M. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation. J. Invest. Dermatol. 2013, 133, 144−153.
(44) Nakano, T.; Goto, S.; Takaoka, Y.; Tseng, H. P.; Fujimura, T.; Kawamoto, S.; Ono, K.; Chen, C. L. A novel moonlight function of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for immuno- modulation. BioFactors 2018, 44, 597−608.
(45) Kornberg, M. D.; Bhargava, P.; Kim, P. M.; Putluri, V.; Snowman, A. M.; Putluri, N.; Calabresi, P. A.; Snyder, S. H. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 2018, 360, 449−453.
(46) Colell, A.; Ricci, J. E.; Tait, S.; Milasta, S.; Maurer, U.; Bouchier-Hayes, L.; Fitzgerald, P.; Guio-Carrion, A.; Waterhouse, N. J.; Li, C. W.; Mari, B.; Barbry, P.; Newmeyer, D. D.; Beere, H. M.; Green, D. R. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007, 129, 983−997.
(47) Wang, H.; Wang, M.; Yang, X.; Xu, X.; Hao, Q.; Yan, A.; Hu, M.; Lobinski, R.; Li, H.; Sun, H. Antimicrobial silver targets glyceraldehyde-3-phosphate dehydrogenase in glycolysis of E. coli. Chem. Sci. 2019, 10, 7193−7199.
(48) Butterfield, D. A.; Hardas, S. S.; Lange, M. L. B. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer’s disease: many pathways to neurodegeneration. J. Alzheimers Dis. 2010, 20, 369−393.
(49) Aronov, A. M.; Verlinde, C. L. M. J.; Hol, W. G. J.; Gelb, M. H. Selective tight binding inhibitors of trypanosomal glyceraldehyde-3- phosphate dehydrogenase via structure-based drug design. J. Med. Chem. 1998, 41, 4790−4799.
(50) Bruno, S.; Pinto, A.; Paredi, G.; Tamborini, L.; De Micheli, C.; La Pietra, V.; Marinelli, L.; Novellino, E.; Conti, P.; Mozzarelli, A. Discovery of covalent inhibitors of glyceraldehyde-3-phosphate dehydrogenase, a target for the treatment of malaria. J. Med. Chem. 2014, 57, 7465−7471.
(51) Galbiati, A.; Zana, A.; Conti, P. Covalent inhibitors of GAPDH: From unspecific warheads to selective compounds. Eur. J. Med. Chem. 2020, 207, 112740.
(52) Kok, B. P.; Ghimire, S.; Kim, W.; Chatterjee, S.; Johns, T.; Kitamura, S.; Eberhardt, J.; Ogasawara, D.; Xu, J.; Sukiasyan, A.; et al. Discovery of small-molecule enzyme activators by activity-based protein profiling. Nat. Chem. Biol. 2020, 16, 997−1005.
論文の公開元へ
